{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:18Z","timestamp":1790409258273,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejca.2024.115157","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:24:41Z","timestamp":1732847081000},"page":"115157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials"],"prefix":"10.1016","volume":"215","author":[{"given":"Kwee","family":"Yong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Roccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Deraedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Kharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Valluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Florendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2024.115157_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/hematology.2020000109","article-title":"Sequencing multiple myeloma therapies with and after antibody therapies","volume":"2020","author":"van de Donk","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"22","key":"10.1016\/j.ejca.2024.115157_bib2","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-16-0861","article-title":"Integration of novel agents into the care of patients with multiple myeloma","volume":"22","author":"Orlowski","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.115157_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma","volume":"11","author":"Lecat","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.115157_bib4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Bruno","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"23","key":"10.1016\/j.ejca.2024.115157_bib5","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.3390\/cancers13235886","article-title":"Stratification for RRMM and risk-adapted therapy: Sequencing of therapies in RRMM","volume":"13","author":"Jeryczynski","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejca.2024.115157_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Dagger) Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2024.115157_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"10068","key":"10.1016\/j.ejca.2024.115157_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejca.2024.115157_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2024.115157_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.ejca.2024.115157_bib12","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/curroncol29030132","article-title":"Sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: a report from the Canadian Myeloma Research Group (CMRG) database","volume":"29","author":"McCurdy","year":"2022","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.115157_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clml.2021.02.004","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma: Real-world analysis of the Pethema-GEM experience","volume":"21","author":"Rodriguez-Otero","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.ejca.2024.115157_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000683","article-title":"Pomalidomide in patients with relapsed and\/or refractory multiple myeloma: A prospective study within the nationwide netherlands cancer registry","volume":"6","author":"Wester","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.ejca.2024.115157_bib15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ejh.13106","article-title":"The efficacy and safety of pomalidomide in relapsed\/refractory multiple myeloma in a \"real-world\" study: Polish Myeloma Group experience","volume":"101","author":"Charlinski","year":"2018","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.ejca.2024.115157_bib16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","article-title":"Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma","volume":"22","author":"Dimopoulos","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.ejca.2024.115157_bib17","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ejca.2024.115157_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.115157_bib19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"10245","key":"10.1016\/j.ejca.2024.115157_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2024.115157_bib21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2024.115157_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ejca.2024.115157_bib23","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2024.115157_bib24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ejca.2024.115157_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"10192","key":"10.1016\/j.ejca.2024.115157_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.115157_bib27","doi-asserted-by":"crossref","unstructured":"Dhakal B., Einsele H., Schecter J.M., et al. Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the Flatiron database. 19th International Myeloma Society Annual Meeting; 2022 August 25; Los Angeles, CA.","DOI":"10.1016\/S2152-2650(22)00571-7"},{"key":"10.1016\/j.ejca.2024.115157_bib28","doi-asserted-by":"crossref","unstructured":"Dhakal B., Einsele H., Potluri R., et al. Real-world treatments and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma treated with 1\u20133 prior lines of therapy, including a PI and IMiD, from the SEER-Medicare database. 19th International Myeloma Society Annual Meeting; 2022 August 25; Los Angeles, CA.","DOI":"10.1097\/01.HS9.0000936312.94801.44"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T21:03:32Z","timestamp":1738875812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":27,"alternative-id":["S0959804924017647"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115157","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115157"}}